SSAA09E2 |
Katalog-Nr.GC62236
One-Click Copy Product Info
|
SSAA09E2 ist ein Inhibitor der SARS-CoV-Replikation (Severe Acute Respiratory Syndrome-Coronavirus), der durch Blockierung frÜher Wechselwirkungen von SARS-S mit dem Rezeptor fÜr SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) , wirkt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 883944-52-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SSAA09E2 is a SARS-CoV replication inhibitor. SSAA09E2 inhibits viral entry into host cells by blocking the interaction between the SARS-CoV spike glycoprotein (S protein) receptor-binding domain (RBD) and the host cell angiotensin-converting enzyme 2 (ACE2) receptor. SSAA09E2 can be used in research related to SARS-CoV and COVID-19[1-4].
In vitro, SSAA09E2 (0-20μM) was used to pre-treat ACE2-transfected 293T cells for 30 minutes, followed by stimulation with SARS-S RBD-Fc for 1 hour. SSAA09E2 significantly inhibited the binding of SARS-S RBD to ACE2[5].
References:
[1] Zhou Y, Wang H, Yang L, et al. Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology. Molecules. 2022 Nov 26;27(23):8257.
[2] Razizadeh M, Nikfar M, Liu Y. Small molecule therapeutics to destabilize the ACE2-RBD complex: A molecular dynamics study. Biophys J. 2021 Jul 20;120(14):2793-2804.
[3] Oany AR, Mia M, Pervin T, et al. Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics. Int J Antimicrob Agents. 2020 Dec;56(6):106177.
[4] Bibi N, Gul S, Ali J, et al. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. Eur J Pharmacol. 2020 Oct 15;885:173496.
[5] Adedeji AO, Severson W, Jonsson C, et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013 Jul;87(14):8017-28.
| Cell experiment [1]: | |
Cell lines | 293T cells (transiently transfected with pCDNA 3.1-ACE2), TZM-bl cells (stably expressing luciferase under the control of the HIV-1 promoter and transfected with pcDNA 3.1-ACE2 plasmid) |
Preparation Method | 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100units/ml penicillin, and 10μg streptomycin. For binding inhibition assays, approximately 1×10⁶ ACE2-transfected 293T cells were detached, washed, and incubated with various concentrations of SSAA09E2 on ice for 30 minutes, followed by addition of purified SARS-CoV spike receptor binding domain-Fc (RBD-Fc) and incubation on ice for 1 hour. For fusion assays, TZM-bl cells expressing ACE2 were overlaid with 293T cells expressing SARS-S envelope and Tat protein, and SSAA09E2 was added either 45 minutes prior to or 2 hours after the overlay. |
Reaction Conditions | 0-20μM; 30 minutes pre-incubation |
Applications | SSAA09E2 significantly inhibited the binding of SARS-S RBD to ACE2 in a dose-dependent manner as measured by flow cytometry. SSAA09E2 also inhibited SARS/HIV pseudotyped virus entry into ACE2-expressing 293T cells with an EC₅₀ of 3.5 ± 0.5μM. In quantitative cell-to-cell fusion assays, SSAA09E2 inhibited fusion when added prior to overlay of SARS-S expressing cells with ACE2-expressing cells. |
References: | |
| Cas No. | 883944-52-3 | SDF | |
| Formula | C16H20N4O2 | M.Wt | 300.36 |
| Löslichkeit | DMSO : 250 mg/mL (832.33 mM; Need ultrasonic) | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3293 mL | 16.6467 mL | 33.2934 mL |
| 5 mM | 665.9 μL | 3.3293 mL | 6.6587 mL |
| 10 mM | 332.9 μL | 1.6647 mL | 3.3293 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)